Chronic Obstructive Pulmonary Disease | Unmet Need | Severe | US/EU | 2018


COPD is a progressive inflammatory respiratory tract and lung disease characterized by airflow obstruction and decreased lung function. The COPD market continues to suffer from the absence of any therapies that can reverse disease progression and repair lung tissue. Smoking cessation is still the only option to slow or halt disease progression, and therapies that can reverse pathological processes and regenerate alveolar tissue have yet to be discovered. In the absence of a truly disease-modifying therapy, inhaled bronchodilator therapies are most commonly prescribed, and development has focused on improving breathing or reducing inflammation. Inhaled medications are primarily effective in reducing the burden of the disease by controlling symptoms, and various clinical trial end points, including FEV1SGRQ, and TDI focal score, are used to try to measure patients’ improvement.


  • What clinical and nonclinical attributes are key influencers to pulmonologists’ prescribing decisions, which have limited impact, and what are potential areas of hidden opportunities?
  • How do market leaders Spiriva, Advair/Seretide, and Symbicort perform on key treatment drivers and goals for COPD? How does their performance compare with one another, as well as that of LABA/LAMAFDCs such as Anoro and Stiolto/Spiolto?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new COPD drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European pulmonologists fielded in May 2018

Key companies: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Sunovion

Key drugs: Spiriva, Advair/Seretide, Symbicort, Breo, Anoro, Stiolto/Spiolto, Utibron/Ultibro, Trelegy

Login to access report

launch Related Market Assessment Reports